Clinical Trial Update: Erlotinib for Treatment of Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial of Tarceva (erlotinib) for psoriasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Northwestern University | Conditions: Psoriasis | Phase 2 | Status: WITHDRAWN